| |
 |
|
Class Information
Number: 514/2
Name: Drug, bio-affecting and body treating compositions > Designated organic active ingredient containing (doai) > Peptide containing (e.g., protein, peptones, fibrinogen, etc.) doai
Description: Subject matter which contains a protein or its reaction product, e.g., peptides, peptones, fibrinogen, etc., wherein the protein molecule is not degraded to the constituent amino-acids.
Sub-classes under this class:
| Class Number |
Class Name |
Patents |
| 514/14 |
12 to 15 peptide repeating units in known peptide chain |
1,113 |
| 514/13 |
16 to 24 peptide repeating units in known peptide chain |
1,149 |
| 514/19 |
2 peptide repeating units in known peptide chain |
1,319 |
| 514/12 |
25 or more peptide repeating units in known peptide chain structure |
5,575 |
| 514/18 |
3 or 4 peptide repeating units in known peptide chain |
1,590 |
| 514/17 |
5 or 6 peptide repeating units in known peptide chain |
1,066 |
| 514/16 |
7 or 8 peptide repeating units in known peptide chain |
1,046 |
| 514/15 |
9 to 11 peptide repeating units in known peptide chain |
1,370 |
| 514/9 |
Cyclopeptides |
696 |
| 514/8 |
Glycoprotein (carbohydrate containing) |
2,029 |
| 514/6 |
Heavy metal containing (e.g., hemoglobin, etc.) |
450 |
| 514/3 |
Insulin or derivative |
604 |
| 514/5 |
Iodine containing |
42 |
| 514/7 |
Phosphorus containing |
196 |
| 514/21 |
Produced by or extracted from animal tissue |
2,376 |
Patents under this class:
| Patent Number |
Title Of Patent |
Date Issued |
| 7612050 |
Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
Nov. 3, 2009 |
| 7612043 |
Method of reducing or inhibiting ObR signaling using a leptin antagonist consisting of SEQ id No: 2 |
Nov. 3, 2009 |
| 7612040 |
Lefty polypeptides and derivatives thereof |
Nov. 3, 2009 |
| 7612038 |
Biglycan and related therapeutics and methods of use |
Nov. 3, 2009 |
| 7612037 |
Cross-linked glycopeptide-cephalosporin antibiotics |
Nov. 3, 2009 |
| 7612036 |
Peptoid compounds |
Nov. 3, 2009 |
| 7612035 |
Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma |
Nov. 3, 2009 |
| 7612034 |
Treatment of subnormal bone mineral density |
Nov. 3, 2009 |
| 7612033 |
Methods for delivering compounds into a cell |
Nov. 3, 2009 |
| 7612032 |
Method for treating oncological diseases |
Nov. 3, 2009 |
| 7611867 |
CC-chemokine binding tick proteins |
Nov. 3, 2009 |
| 7608590 |
HCV NS-3 serine protease inhibitors |
Oct. 27, 2009 |
| 7608582 |
Delivery vehicle comprising a modified MscL protein channel |
Oct. 27, 2009 |
| 7608581 |
Biofunctional, antimicrobial coatings for medical devices |
Oct. 27, 2009 |
| 7608580 |
Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins |
Oct. 27, 2009 |
| 7608579 |
Lung volume reduction using glue compositions |
Oct. 27, 2009 |
| 7608578 |
Obesity controlling method |
Oct. 27, 2009 |
| 7608577 |
Peptidyl ketones as inhibitors of DPIV |
Oct. 27, 2009 |
| 7608284 |
Enamel matrix protein composition for treatment of systemic inflammatory response syndrome |
Oct. 27, 2009 |
| 7608269 |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
Oct. 27, 2009 |
| 7608268 |
Ferritin fusion proteins for use in vaccines and other applications |
Oct. 27, 2009 |
| 7608261 |
VEGF antagonist formulations suitable for intravitreal administration |
Oct. 27, 2009 |
| 7605150 |
Drug therapy for Celiac Sprue |
Oct. 20, 2009 |
| 7605130 |
Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction |
Oct. 20, 2009 |
| 7605129 |
Splice variant of human placental growth hormone |
Oct. 20, 2009 |
| 7605125 |
DNA-binding polyamide drug conjugates |
Oct. 20, 2009 |
| 7605123 |
Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof |
Oct. 20, 2009 |
| 7605122 |
Human chorionic gonadotropin (hCG) formulations for facilitating weight loss and body contouring |
Oct. 20, 2009 |
| 7605121 |
Oligopeptide lyophilisate, their preparation and use |
Oct. 20, 2009 |
| 7605120 |
Antagonists of the brandykinin B1 receptor |
Oct. 20, 2009 |
| 7605119 |
Memory enhancing protein method |
Oct. 20, 2009 |
| 7604950 |
Methods for early detection of pregnancy in cows |
Oct. 20, 2009 |
| 7604931 |
Cripto mutant and uses thereof |
Oct. 20, 2009 |
| 7601705 |
Polymer controlled induced viscosity fiber system and uses thereof |
Oct. 13, 2009 |
| 7601690 |
Cross-linked glycopeptide-cephalosporin antibiotics |
Oct. 13, 2009 |
| 7601687 |
Mechanism for identifying drugs for the treatment of type II diabetes |
Oct. 13, 2009 |
| 7601686 |
Hepatitis C virus inhibitors |
Oct. 13, 2009 |
| 7601685 |
Growth factor modified protein matrices for tissue engineering |
Oct. 13, 2009 |
| 7601684 |
Diagnosis and treatment of disorders of iron metabolism |
Oct. 13, 2009 |
| 7601683 |
Protein conformational isomers, methods of making, methods for using, compositions comprising and products made therewith |
Oct. 13, 2009 |
| 7601540 |
Gamma secretase notch biomarkers |
Oct. 13, 2009 |
| 7601516 |
Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility |
Oct. 13, 2009 |
| 7601341 |
Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis |
Oct. 13, 2009 |
| 7598219 |
Implants comprising an osteoinductive factor and a contrast agent compatible therewith |
Oct. 6, 2009 |
| 7595296 |
Mutant polypeptides of fibroblast growth factor 1 |
Sep. 29, 2009 |
| 7595294 |
Vasoactive intestinal polypeptide pharmaceuticals |
Sep. 29, 2009 |
| 7595293 |
Stable pharmaceutical compositions |
Sep. 29, 2009 |
| 7595292 |
Conjugated biological molecules and their preparation |
Sep. 29, 2009 |
| 7595062 |
Joint resurfacing orthopaedic implant and associated method |
Sep. 29, 2009 |
| 7595056 |
Methods of rejuvenating Leydig cells and enhancing testosterone production in a male subject |
Sep. 29, 2009 |
|
|
|
